Suzanne L. Tinsley, PT, PhDLouisiana State University Health Sciences Center

Shreveport, LA

PHARMACOLOGYPrinciples of Pharmacotherapeutics

Independent Study Course 28.4.3 Reissued from ISC 16.1.1

CONTINUING PHYSICAL THERAPY EDUCATION

16

1. Holford NH, Sheiner LB. Understanding the dose-ef-fect relationship: clinical application of pharmacoki-netic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429-453.

2. Ross EM, Kenakin TP. Pharmacodynamics. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2001:31-45.

3. Duggan AW, North RA. Electrophysiology of opioids. Pharmacol Rev. 1983;35(4):219-281.

4. Goodman RR, Pasternak GW. Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. Proc Natl Acad Sci U S A. 1985;82(19):6667–6671.

5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411-1420.

6. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002;1(1):37-44.

7. Bourne H, von Zastrow M. Drug receptors and pharma-codynamics. In: Katzung B, ed. Basic and Clinical Phar-macology. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:11-33.

8. Katzung B, ed. Basic and Clinical Pharmacology, 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004.

9. Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, Medical Publish-ing Division; 2001.

10. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB, Gaffney TE. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol. 1988;37(1):115-124.

11. World Health Organization. Technical Report Series. Gene-va, Switzerland: World Health Organization; 1966.

12. Oates JA. The science of drug therapy. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman’s The Phar-macological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2006:117-136.

13. Reuter I, Harder S, Engelhardt M, Baas H. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2000;15(5):862-868.

14. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol phar-macokinetics and pharmacodynamics in healthy volun-teers. Clin Pharmacol Ther. 1999;66(6):594-601.

15. Hinderling PH, Tendolkar A, Dee CM, Barr WH, Seiber-ling M, Duerr H. Single-dose interaction study of diprafe-

none HCl and propranolol HCl in healthy volunteers. J Clin Pharmacol. 1995;35(7):721-729.

16. Buxton ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action and elimination. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman’s The Pharmacological Basis of Ther-apeutics. 11th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2006:1–39.

17. Flynn EJ. Pharmacodynamic and pharmacokinetic prin-ciples of pharmacology and drug therapy. J Neurol Phys Ther. 2003;27:93-100.

18. Cross JH. Reevaluation of the employment of Fick’s law for diffusion dosimeters. Environ Sci Technol. 2003;37(8):1633-1638.

19. Duhlmeier R, Hacker A, Widdel A, von Engelhardt W, Sallmann HP. Mechanisms of insulin-dependent glucose transport into porcine and bovine skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2005;289(1):R187–R197.

20. Holford NHG. Pharmacokinetics and pharmacodynam-ics: rational dosing and the time course of drug action. In: Katzung B, ed. Basic and Clinical Pharmacology. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:34-50.

21. Potts RO, Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. Obstet Gynecol. 2005;105(5 pt 1):953-961.

22. Correia M. Drug biotransformation. In: Katzung B, ed. Basic and Clinical Pharmacology. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:51-63.

23. Dossing M. Effect of acute and chronic exercise on hepat-ic drug metabolism. Clin Pharmacokinet. 1985;10(5):426-431.

24. Lenz TL, Lenz NJ, Faulkner MA. Potential interac-tions between exercise and drug therapy. Sports Med. 2004;34(5):293-306.

25. McArdle WD, Katch FL, Katch VL. Exercise Physiology, Energy, Nutrition and Human Performance. 3rd ed. Phila-delphia, PA: Lea & Febiger; 1991.

26. Brouns F, Saris WH, Rehrer NJ. Abdominal complaints and gastrointestinal function during long-lasting exercise. Int J Sports Med. 1987;8(3):175-189.

27. Cordain L, Latin RW, Behnke JJ. The effects of an aerobic running program on bowel transit time. J Sports Med Phys Fitness. 1986;26(1):101-104.

28. Klemsdal TO, Gjesdal K, Bredesen JE. Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin. Eur J Clin Pharmacol. 1992;43(6):625-628.

REFERENCES

17

29. van Baak MA. Influence of exercise on the pharmacoki-netics of drugs. Clin Pharmacokinet. 1990;19(1):32-43.

30. Villa JG, Bayon JE, Gonzalez-Gallego J. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning. J Sports Med Phys Fitness. 1999;39(3):197-201.

31. Stoschitzky K, Lindner W, Klein W. Stereoselective release of (S)-atenolol from adrenergic nerve endings at exercise. Lancet. 1992;340(8821):696-697.

32. Ylitalo P, Hinkka H. Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide. Int J Clin Pharmacol Ther Toxicol. 1985;23(10):548-553.

33. Ciccone CD. Basic pharmacokinetics and the potential effect of physical therapy interventions on pharmacokinet-ic variables. Phys Ther. 1995;75(5):343-351.